Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell vaccines.

Paul J Mosca1, H Kim Lyerly, Timothy M Clay

  • 1Duke Comprehensive Cancer Center Duke University Medical Center, Durham, NC 27710, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|May 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laparoscopy versus laparotomy for pediatric patients with abdominal firearm injuries.

American journal of surgery·2026
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026
Same author

Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves.

Circulation. Cardiovascular interventions·2026
Same author

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications·2025
Same journal

The CD44 protein family: roles in embryogenesis and tumor progression.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Four varieties of voltage-gated proton channels.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Lurie's tubercle-count method to test TB vaccine efficacy in rabbits.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Optical spectroscopy of breast biopsies and human breast cancer xenografts in nude mice.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

The colostrum-deprived, artificially-reared, neonatal pig as a model animal for studying rotavirus gastroenteritis.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Action of polypeptide growth factors in colon cancer; development of new therapeutic approaches.

Frontiers in bioscience : a journal and virtual library·2017
See all related articles

Dendritic cell cancer vaccines show safety and feasibility in early trials. Research now focuses on enhancing the potency of these dendritic cell (DC) immunotherapies for better cancer treatment outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are crucial antigen-presenting cells that activate tumor-specific T cells.
  • Preclinical studies demonstrate the potential of DCs in stimulating anti-tumor immune responses.
  • This has led to significant interest in developing DC-based cancer vaccines.

Purpose of the Study:

  • To review the progress and current state of dendritic cell-based cancer vaccine research.
  • To highlight the safety and feasibility demonstrated in early-phase clinical trials.
  • To identify the future direction of DC immunotherapy, focusing on enhancing vaccine potency.

Main Methods:

  • Review of preclinical studies on dendritic cell function in cancer immunity.
  • Analysis of data from early-phase clinical trials of dendritic cell immunotherapies.

Related Experiment Videos

  • Examination of various methods for generating, loading, and administering dendritic cells.

    • Main Results:

    • Early clinical trials confirm the safety and feasibility of dendritic cell immunotherapies.
    • Preliminary clinical and immunological data suggest potential efficacy.
    • Current research emphasizes strategies to improve the potency of DC vaccine preparations.

    Conclusions:

    • Dendritic cell-based cancer vaccines are a promising area of cancer immunotherapy.
    • While safe and feasible, further optimization is needed to enhance clinical effectiveness.
    • Future research will concentrate on increasing the potency of dendritic cell vaccines to improve patient outcomes.